ArticleScientific reports2026
Patient-derived 3D organotypic co-cultures as a long-term ex vivo model for pleomorphic adenoma of the parotid gland.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleomorphic adenoma is the most common benign salivary gland tumor and most frequently arises in the parotid gland. Although benign, it can recur and may undergo malignant transformation, underscoring the need for experimental models that preserve native tissue features over time. In this study, fresh tumor tissue from six patients with primary histologically benign pleomorphic adenoma was divided into fragments of approximately 3 × 3 mm in surface dimensions and approximately 3 mm in thickness and maintained in a patient-derived three-dimensional organotypic co-culture for up to 21 days. The primary longitudinal analysis compared baseline tissue with matched fragments harvested at days 14 and 21. Histology and immunohistochemistry were assessed in three randomly selected high-power fields within morphologically viable, tumor-containing regions; necrotic or degenerative areas were excluded. Ki-67-positive cell nuclei remained within the predefined low category at all retained time points. PLAG1 positivity was retained in all cases but was more variable by day 21, while epithelial and myoepithelial-associated markers showed marker- and case-dependent patterns. CD45-positive cells remained detectable in sampled viable compartments, whereas SSTR2 was commonly reduced after baseline. These findings support the use of the 3D-OTC platform for longitudinal histomorphologic and selected biomarker assessment within surviving viable tissue compartments. Because whole-fragment necrosis and diffusion of oxygen, nutrients, or test compounds were not quantified, the present data do not establish uniform full-thickness viability or validate the platform for therapeutic-response testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.